

Pharmacologic Agents for Treatment of Hepatitis C

SCAN Formulary Drugs

Medication	Dosing & Administration	2020 Formulary Status		2021 Formulary Status		Adverse Drug Reactions
		Tier	UM	Tier	UM	
Combination Direct-Acting Antivirals						
EPCLUSA	sofosbuvir/velpatasvir (400 mg/100mg) PO daily	5	[PA]	5	[PA]	Nausea, Headache, fatigue, bradyarrhythmia
HARVONI	ledipasvir/sofosbuvir (90mg/400mg) PO daily	5	[PA]	5	[PA]	Bradycardia if used with amiodarone, fatigue, headache
LEDIPASVIR/ SOFOSBUVIR 90mg-400mg	ledipasvir/sofosbuvir (90mg/400mg) PO daily	5	[PA]	5	[PA]	Bradycardia if used with amiodarone, fatigue, headache
<i>ribavirin</i>	400mg to 600mg PO BID	3		3		Fatigue/ asthenia, pyrexia, myalgia, headache Boxed warning: hemolytic anemia may result in worsening of cardiac disease and myocardial infarctions
SOFOSBUVIR/ VELPATASVIR 400mg-100mg	sofosbuvir/velpatasvir (400 mg/100mg) PO daily	5	[PA]	5	[PA]	Nausea, Headache, fatigue, bradyarrhythmia
ImmunostimulantsPegylated Interferon						
PEGASYS INJ	180mcg SQ once weekly	5		5		Fatigue/ asthenia, pyrexia, myalgia, and headache Boxed warning: may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders
PEGASYS PROCLICK INJ	180mcg SQ once weekly	5		5		

Brand-name drugs are capitalized and generic drugs are listed in the lower-case italics.

[NF] = Non-formulary

[PA] = Prior Authorization



Drug Reference:

1. Online Lexicomp (08/2020): 1100 Terex Road, Hudson, OH 44236
2. Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. May 2018. <http://www.hcvguidelines.org/> (Accessed on August 13, 2020)